This is a discussion on Meta-Analysis Finds Early Signs of Rofecoxib (Vioxx) Cardiovascular Risk within the Pain Management forums, part of the General Spine Discussion Forums category; The rofecoxib (Vioxx) saga continues with the publication today of a meta-analysis suggesting that the drug's maker, Merck, had evidence ...
Meta-Analysis Finds Early Signs of Rofecoxib (Vioxx) Cardiovascular Risk The rofecoxib (Vioxx) saga continues with the publication today of a meta-analysis suggesting that the drug's maker, Merck, had evidence of a link to increased risk of heart attack and stroke more than three years before the company pulled the drug from the market...
Meta-Analysis Finds Early Signs of Rofecoxib (Vioxx) Cardiovascular Risk (click here for the full article at MedPage Today)
Justin Averna
Founder & President, Spine Patient Society™
www.SpinePatientSociety.org
A 501(c)(3) Tax-Exempt Nonprofit & Charitable Organization
I'm here to help.
- 1994: Football Injury, Severe Hyperextension
- 1997: Snow Skiing Injury
- 3/7/1997, 17 years old: Laminotomy L4/L5
- 1999 & 2003: Motor Vehicle Accidents (not at fault both times) --> Grade V Annular Tears L4/L5 & L5/L6
- 11/15/2003, 23 years old: 2-Level ProDisc® L4/L5 & L5/L6*, *lumbosacral transitional vertebra --> Dr. Rudolf Bertagnoli
- 4/2008: 4.5 years pain-free before "new" leg pain
- 5/14/2009, 29 years old: Dynamic Stabilization System L4/L5, Dr. Rudolf Bertagnoli
Questions? Suggestions? Need help with registering, creating a signature, etc.?
justin (at) spinepatientsociety.org
Disclosure: I have no financial relationships with any surgeons, spine clinics, device manufacturers, pharmaceutical companies, hospitals, etc. -- the SPS Board of Directors serve without compensation.
Posting Permissions
LinkBack URL
About LinkBacks
Reply With Quote
Bookmarks